Page 50 - Read Online

Page 20 of 23 ALHulais et al. J Cancer Metastasis Treat 2019;5:3 I http://dx.doi.org/10.20517/2394-4722.2018.71

murine homologue. J Natl Cancer Inst 1998;90:691-7.
110. Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, et al. Expression of Ep-CAM shifts the state of cadherin-
mediated adhesions from strong to weak. Exp Cell Res 2003;285:50-8.
111. Maetzel D, Denzel S, Mack B, Canis M, Went P, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-71.
112. Schmidt M, Ruttinger D, Sebastian M, Hanusch CA, Marschner N, et al. Phase IB study of the EpCAM antibody adecatumumab combined
with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol 2012;23:2306-13.
113. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet
2000;356:1981-2.
114. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast
cancer. Breast Cancer Res Treat 2004;86:207-13.
115. Bokemeyer C. Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 2010;10:1259-69.
116. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23.
117. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, et al. Stem cell and epithelial-mesenchymal transition markers are frequently
overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.
118. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999;77:699-712.
119. Trzpis M, McLaughlin PM, van Goor H, Brinker MG, van Dam GM, et al. Expression of EpCAM is up-regulated during regeneration of
renal epithelia. J Pathol 2008;216:201-8.
120. Imai T, Tamai K, Oizumi S, Oyama K, Yamaguchi K, et al. CD271 defines a stem cell-like population in hypopharyngeal cancer. PLoS One
2013;8:e62002.
121. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, et al. Human melanoma-initiating cells express neural crest nerve
growth factor receptor CD271. Nature 2010;466:133-7.
122. Tomellini E, Lagadec C, Polakowska R, Le Bourhis X. Role of p75 neurotrophin receptor in stem cell biology: more than just a marker. Cell
Mol Life Sci 2014;71:2467-81.
123. Watson JT, Foo T, Wu J, Moed BR, Thorpe M, et al. CD271 as a marker for mesenchymal stem cells in bone marrow versus umbilical cord
blood. Cells Tissues Organs 2013;197:496-504.
124. Alvarez-Viejo M, Menendez-Menendez Y, Otero-Hernandez J. CD271 as a marker to identify mesenchymal stem cells from diverse sources
before culture. World J Stem Cells 2015;7:470-6.
125. Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, et al. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity
and stem-like properties of melanoma cells. PLoS One 2014;9:e92596.
126. Li S, Yue D, Chen X, Wang L, Li J, et al. Epigenetic regulation of CD271, a potential cancer stem cell marker associated with
chemoresistance and metastatic capacity. Oncol Rep 2015;33:425-32.
127. Huang SD, Yuan Y, Liu XH, Gong DJ, Bai CG, et al. Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal
squamous cell carcinomas. BMC Cancer 2009;9:9.
128. Kojima H, Okumura T, Yamaguchi T, Miwa T, Shimada Y, et al. Enhanced cancer stem cell properties of a mitotically quiescent
subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma. Int J Oncol 2017;51:49-62.
129. Okumura T, Yamaguchi T, Watanabe T, Nagata T, Shimada Y. Flow cytometric detection of circulating tumor cells using a candidate stem
cell marker, p75 neurotrophin receptor (p75NTR). Methods Mol Biol 2017;1634:211-7.
130. Chung MK, Jung YH, Lee JK, Cho SY, Murillo-Sauca O, et al. CD271 Confers an invasive and metastatic phenotype of head and neck
squamous cell carcinoma through the upregulation of slug. Clin Cancer Res 2018;24:674-83.
131. Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFN-gamma-inducible immunosuppressive factor that mediates
downregulation of melanoma antigens. J Invest Dermatol 2014;134:1369-77.
132. Redmer T, Walz I, Klinger B, Khouja S, Welte Y, et al. The role of the cancer stem cell marker CD271 in DNA damage response and drug
resistance of melanoma cells. Oncogenesis 2017;6:e291.
133. Radke J, Rossner F, Redmer T. CD271 determines migratory properties of melanoma cells. Sci Rep 2017;7:9834.
134. Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, et al. Human CD271-positive melanoma stem cells associated with metastasis
establish tumor heterogeneity and long-term growth. Cancer Res 2011;71:3098-109.
135. Guo R, Fierro-Fine A, Goddard L, Russell M, Chen J, et al. Increased expression of melanoma stem cell marker CD271 in metastatic
melanoma to the brain. Int J Clin Exp Pathol 2014;7:8947-51.
136. Redmer T. Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. Mol Cancer 2018;17:106.
137. Csermely P, Hodsagi J, Korcsmaros T, Modos D, Perez-Lopez AR, et al. Cancer stem cells display extremely large evolvability: alternating
plastic and rigid networks as a potential mechanism: network models, novel therapeutic target strategies, and the contributions of hypoxia,
inflammation and cellular senescence. Semin Cancer Biol 2015;30:42-51.
138. Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, et al. Isolation and characterization of mesenchymal cells from human fetal membranes.
J Tissue Eng Regen Med 2007;1:296-305.
139. Marconi A, Borroni RG, Truzzi F, Longo C, Pistoni F, et al. Hypoxia-inducible factor-1alpha and CD271 inversely correlate with melanoma
invasiveness. Exp Dermatol 2015;24:396-8.
140. Beretti F, Manni P, Longo C, Argenziano G, Farnetani F, et al. CD271 is expressed in melanomas with more aggressive behaviour, with
correlation of characteristic morphology by in vivo reflectance confocal microscopy. Br J Dermatol 2015;172:662-8.
141. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation.
Oncogene 2012;31:4898-911.
142. Saltari A, Truzzi F, Quadri M, Lotti R, Palazzo E, et al. CD271 down-regulation promotes melanoma progression and invasion in three-
dimensional models and in zebrafish. J Invest Dermatol 2016;136:2049-58.
143. Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, et al. Low neurotrophin receptor CD271 regulates phenotype switching in